New drug is the first recombinant single-chain therapy. Its long-lasting action may allow some patients to infuse twice weekly.
MASAC Document #242 is a valuable resource for understanding supply of clotting factor concentrate doses for home use by individuals with bleeding disorders.
Researchers found that previously-untreated patients (PUPs) had a significantly higher incidence of inhibitors when treated with recombinant factor VIII than those treated with plasma-derived factor VIII.
Abstracts are due by Monday, June 6, 2016.
September educational workshop in Columbus, OH, will focus on the clinical care of patients with hemophilia and inhibitors.
This chapter provides nurses with best practices to guarantee that a child’s physical and academic needs are being met at school.
We applaud all of our hard-working nurses during National Nurses Week, which begins Friday, May 6th.
Eligible candidates pursuing hemostasis and/or thrombosis research should apply now for two research-related awards.
Patients with previous hepatitis B infection, cirrhosis or hepatocellular carcinoma need follow-up after treatment with direct-acting antivirals.
Scientists from the Indiana HTC and MicroHealth present the results of a 12-month study on the effect of HTC digital monitoring on annual bleeding rates.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car